BioStar gains distribution of chlamydia test:
This article was originally published in Clinica
Executive Summary
General Injectables and Vaccines has added BioStar's Chlamydia Optical ImmunoAssay point-of-care test to the antibiotic Zithromax which it is already distributing for Pfizer. General Injectables agreed a joint marketing deal with BioStar, a privately-held company in Boulder, Colorado, which specialises in developing point-of-care tests for infectious diseases.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.